Clifford Chance is advising the Special Committee of Directors of biopharmaceuticals group Stallergenes Greer (EPA: STAGR) in relation to the recommended acquisition of the company by its controlling shareholder Waypoint. The transaction, announced today, values the company at approximately €730 million.
Waypoint currently owns approximately 84% of the company. Upon completion of the acquisition, which will be implemented through a scheme of arrangement, the company will be de-listed from Euronext Paris.
Waypoint Corporation provides air taxi and VLJ management services in the Midwest and Mid-Atlantic States. The company provides JetCare and JetCare-Plus services which handle and maintain the company’s operations.
Stallergenes Greer plc, a biopharmaceutical company, engages in the diagnosis and treatment of allergies worldwide. The company develops and commercializes allergy immunotherapy products and services. It also offers sublingual products consisting of Staloral liquid sublingual drops placed under the tongue; Actair, a house dust mite tablet; and Oralair solid sublingual dissolving tablets placed under the tongue.
The Clifford Chance team is led by Corporate Partners Joel Ziff (Picture), Gilles Lebreton and Aline Cardin (both Paris).
Law Firms: Clifford Chance;